Unicycive Therapeutics
UNCY
95 hedge funds and large institutions have $53.5M invested in Unicycive Therapeutics in 2026 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 38 increasing their positions, 17 reducing their positions, and 11 closing their positions.
145% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 11
124% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 17
20% more funds holding
Funds holding: 79 → 95 (+16)
4% less capital inflows, than outflows
Capital inflows: $14.5M | Capital outflows: $15.1M
10% less call options, than puts
Call options by funds: $2.11M | Put options by funds: $2.34M
1.44% less ownership
Funds ownership: 42.39% → 40.95% (-1.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
+$2.01M |
| 2 |
Eversept Partners
New York
|
+$1.74M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$1.4M |
| 4 |
Millennium Management
New York
|
+$1.17M |
| 5 |
Jane Street
New York
|
+$1.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Octagon Capital Advisors
New York
|
-$3.76M |
| 2 |
Vivo Capital
Palo Alto,
California
|
-$2.58M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$2.14M |
| 4 |
Diadema Partners
Morristown,
New Jersey
|
-$1.57M |
| 5 |
J. Goldman & Co
New York
|
-$1.34M |
UNCY Hedge Fund Activity: Q3 2026 in Review
95 of the 8,220 institutional investors tracked by Wall St. Rank reported a position in Unicycive Therapeutics (UNCY) for Q3 2026, worth a combined $53.5M — down 2% from $54.6M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new UNCY positions and 11 closed out — a net gain of 16 holders — while 38 added to existing stakes and 17 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $2.01M. The largest seller was Octagon Capital Advisors, cutting an estimated $3.76M.
- 95 institutional investors held Unicycive Therapeutics (UNCY) as of Q3 2026, up from 79 in Q2 2026.
- Funds reported $53.5M of Unicycive Therapeutics stock for Q3 2026, down 2% quarter-over-quarter.
- 27 funds opened new Unicycive Therapeutics positions in Q3 2026 and 11 closed out, a net change of +16 holders.
- The largest Unicycive Therapeutics buyer in Q3 2026 was OrbiMed, an estimated $2.01M added.
- The largest Unicycive Therapeutics seller in Q3 2026 was Octagon Capital Advisors, an estimated $3.76M sold.
Based on aggregated 13F filings for Q3 2026.